UnitedHealth Group Incorporated
UNH · NYSE
Next quarter
Reports Oct 27, 2026.
Consensus is $4.03 EPS for Sep 2026 across 10 estimates, ranging $3.66 to $4.56.
UNH Jun 2026
- 29.15%
- +0.64%
- $4.94
- $6.38
- —
- $112.03B
Reported results
- $112.03B
- 88.06%
- $7.99B
- 7.13%
- $5.48B
- $6.04
Highlights
- Earnings beat: Adjusted EPS was $6.38 versus the $4.94 consensus, a 29.15% surprise; reported diluted EPS was $6.04 versus $3.74 a year ago.
- Profit recovery: Revenue was $112.0 billion, up from $111.6 billion a year ago, while earnings from operations rose to $8.0 billion from $5.2 billion and net margin improved to 4.9% from 3.1%.
- Medical costs: The medical care ratio fell to 86.7% from 89.4%, supported by pricing discipline, benefit design and medical-cost management; $860 million of favorable prior-period reserve development also benefited the quarter.
- UnitedHealthcare margins: UnitedHealthcare operating earnings increased to $3.9 billion from $2.1 billion, with operating margin expanding to 4.6% from 2.4%, despite revenue of $86.0 billion being essentially flat year over year.
- Enrollment pressure: UnitedHealthcare served 48.5 million people, down 525,000 sequentially; Medicare Advantage and related complex-population enrollment fell by 965,000 from year-end 2025.
- Optum improvement: Optum operating earnings rose to $4.0 billion from $3.1 billion, with margin expanding 160 basis points to 6.2% despite revenue declining to $65.7 billion from $67.2 billion.
- Guidance raised: Full-year adjusted EPS guidance increased to $19.50-$20.00 from above $17.75, while reported EPS guidance moved to $18.45-$18.95 from above $17.10.
- Cash and capital: Operating cash flow was $11.1 billion, or 1.9 times net income; UnitedHealth had repurchased $4.0 billion of stock through mid-July and expects at least $5.0 billion of repurchases in 2026.
Analysis
UnitedHealth’s second quarter was a substantial earnings beat, led by lower medical costs and stronger operating performance across both major businesses. Adjusted EPS of $6.38 exceeded the $4.94 consensus by 29.15% and rose from $4.08 in the year-ago quarter, while reported EPS was $6.04 versus $3.74. Revenue of $112.0 billion was broadly unchanged from $111.6 billion a year ago and $111.7 billion in the first quarter, but operating earnings increased 55% year over year to $8.0 billion. Sequentially, operating earnings declined from $9.0 billion and reported EPS from $6.90, reflecting the normal quarterly pattern.
The defining feature was an 86.7% medical care ratio, down 270 basis points year over year and helped by $860 million of favorable prior-period development. UnitedHealthcare’s margin consequently recovered to 4.6%, although membership declined to 48.5 million, including a 965,000 reduction in Medicare Advantage and related complex-population enrollment from year-end. Optum supplied the other major support: operating earnings rose 32% to $4.0 billion and margin expanded to 6.2%, despite lower revenue and fewer Optum Health value-based-care patients. Management raised full-year adjusted EPS guidance to $19.50-$20.00 from above $17.75, citing year-to-date performance and a better outlook for the balance of the year.
Medical cost recovery
The quarter’s largest earnings driver was the sharp improvement in medical-cost performance. UnitedHealth’s medical care ratio was 86.7%, compared with 89.4% in the second quarter of 2025 and 88.1% for the full-year 2026 guidance midpoint. Management attributed the improvement to benefit design changes, better-aligned pricing, member mix, medical management and cost discipline. Net favorable prior-period development totaled $860 million, with most of it related to 2026 dates of service, providing an additional lift to the reported result.
- Operating leverage: Consolidated earnings from operations increased to $7.99 billion from $5.15 billion, even as revenue rose only 0.4% to $112.03 billion.
- Investment spending: The operating cost ratio increased to 12.7% from 12.3%, reflecting targeted spending on technology, artificial intelligence, infrastructure, care delivery, consumer experience and community support.
UnitedHealthcare enrollment
UnitedHealthcare delivered a marked margin recovery, but its membership base continued to contract. Revenue was $86.0 billion, essentially unchanged from $86.1 billion a year ago, while operating earnings rose to $3.9 billion from $2.1 billion and operating margin doubled to 4.6% from 2.4%. The improvement reflected medical and operating cost management, pricing discipline and benefit design changes.
- Total membership: Medical membership declined to 48.525 million from 50.115 million a year ago and 49.050 million at the end of the first quarter.
- Medicare: Medicare & Retirement revenue was $42.4 billion versus $42.6 billion a year ago, as fewer seniors were served; Medicare Advantage and related complex-population enrollment was down 965,000 from year-end 2025.
- Community and State: Revenue was $23.6 billion versus $23.7 billion, while people served fell by 380,000, primarily because of the planned Louisiana health-plan exit and continuing Medicaid eligibility requirements.
- Employer and Individual: Revenue increased to $20.0 billion from $19.8 billion, although membership declined by 145,000 because of attrition in self-funded and fully insured employer products.
Optum margin expansion
Optum was the second major contributor to the print. Revenue decreased 2.3% to $65.7 billion from $67.2 billion, but operating earnings rose to $4.0 billion from $3.1 billion and operating margin expanded to 6.2% from 4.6%, a 160-basis-point year-over-year improvement.
- Optum Health: Revenue fell 5% to $23.5 billion as value-based-care patients served declined by about 700,000, but operating earnings rose to $1.2 billion and margin reached 5.1% on operational improvements and medical-cost management.
- Optum Insight: Revenue was $5.4 billion and operating earnings increased to $1.4 billion from $1.2 billion, aided by operational improvements and contract timing. The business continued introducing AI-enabled coding and digital prior-authorization tools and completed its Alegeus acquisition on July 2.
- Optum Rx: Revenue was $38.3 billion versus $38.5 billion, while operating earnings increased to $1.5 billion from $1.4 billion, supported by specialty-generic adoption and operating improvements. Adjusted scripts fell to 387 million from 414 million because of membership declines.
Raised outlook and capital
UnitedHealth raised its 2026 outlook after the strong first half and improved expectations for the remainder of the year. Reported EPS is now expected at $18.45-$18.95, versus the prior expectation of more than $17.10, and adjusted EPS at $19.50-$20.00 versus more than $17.75. Consolidated operating earnings guidance increased to more than $25.45 billion from more than $24.0 billion, including higher targets for UnitedHealthcare, Optum Health and Optum Insight.
- Cash generation: First-half operating cash flow was $19.96 billion versus $12.64 billion a year ago; second-quarter cash flow was $11.1 billion, helped by the timing of a substantial government payment.
- Balance sheet: Debt-to-capital was 41.2% at June 30, down from 42.9% at the end of the first quarter and 44.1% a year ago, with management targeting approximately 40% by year-end.
- Share repurchases: The company repurchased $4.0 billion of stock through mid-July and raised its 2026 target to at least $5.0 billion from approximately $2.5 billion.
Healthcare simplification
Alongside the financial results, UnitedHealth emphasized reforms intended to improve affordability, transparency and the care-provider experience. The company committed $1 billion to the United Health Foundation, said it would eliminate 30% of current prior-authorization volume by the end of 2026, and plans to remove nearly two-thirds of prior-authorization requirements for pediatric care. It also committed to passing through 100% of manufacturer drug rebates to clients by January 1, 2028, and launched a fee-based pharmacy model designed to eliminate spread pricing and volume-based incentives.
